Abstract
Objective
Methods
Results
ACKNOWLEDGMENTS
Notes
CONFLICT OF INTEREST
Dr. Yoon-Kyoung Sung has received research funding or speaker fees from BMS, Eisai, JW pharmaceuticals, Pfizer and Yuhan. Yusun Lee is an employee of Abbvie. Dr. Myeoung-su Lee, Chang Hoon Lee, Hye Soon Lee, Jung Ran Choi, Kyungsu Park, Mi-Kyoung Lim, Byoong Yong Choi, Hyoun-Ah Kim, Seung Won Choi, and Wan-Hee Yoo have no conflict of interest.
AUTHOR CONTRIBUTIONS
M.L., C.H.L., H.S.L., Y.K.S., J.R.C., K.P., M.K.L., B.Y.C., H.A.K., S.W.C., Y.L. and W.H.Y. contributed to the study concept and design. Material preparation, data collection and analysis were performed by M.L. and W.H.Y. The first draft of the manuscript was written by M.L. and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.
REFERENCES
![crossref](/image/icon/bnr_ref_cross.gif)
![pmid](/image/icon/bnr_ref_pmid.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![pmid](/image/icon/bnr_ref_pmid.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![pmid](/image/icon/bnr_ref_pmid.gif)
![pmid](/image/icon/bnr_ref_pmid.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![pmid](/image/icon/bnr_ref_pmid.gif)
![pmid](/image/icon/bnr_ref_pmid.gif)
![pmid](/image/icon/bnr_ref_pmid.gif)
![pmc](/image/icon/bnr_ref_PMC.gif)
![pmid](/image/icon/bnr_ref_pmid.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![pmid](/image/icon/bnr_ref_pmid.gif)
![pmid](/image/icon/bnr_ref_pmid.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![pmid](/image/icon/bnr_ref_pmid.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![pmid](/image/icon/bnr_ref_pmid.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![pmid](/image/icon/bnr_ref_pmid.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![pmid](/image/icon/bnr_ref_pmid.gif)
![pmc](/image/icon/bnr_ref_PMC.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![pmid](/image/icon/bnr_ref_pmid.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![pmid](/image/icon/bnr_ref_pmid.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![pmid](/image/icon/bnr_ref_pmid.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![pmid](/image/icon/bnr_ref_pmid.gif)
![pmc](/image/icon/bnr_ref_PMC.gif)
Table 1
Characteristic | Patients (n=91) |
---|---|
Age (yr) | 55.7±13.3 |
Age group | |
18∼34 yr | 7 (7.7) |
35∼44 yr | 9 (9.9) |
45∼54 yr | 18 (19.8) |
55∼64 yr | 34 (37.4) |
65∼74 yr | 18 (19.8) |
≥75 yr | 5 (5.5) |
Sex, female | 64 (70.3) |
Disease duration* (yr) | 7.67±7.34 |
Comorbidities | 23 (25.3) |
Diabetes | 9 (9.9) |
Chronic pulmonary disease | 5 (5.5) |
Cerebrovascular disease | 4 (4.4) |
DAS28† | 6.1±1.0 |
DAS28 categorization | |
Moderate disease activity | 6 (6.6) |
High disease activity | 85 (93.4) |
Concomitant disease modifying antirheumatic drug | 28 (30.8) |
Methotrexate | 23 (25.3) |
Leflunomide | 13 (14.3) |
Hydroxychloroquine | 11 (12.1) |
Sulfasalazine | 3 (3.3) |
Concomitant oral steroids | 23 (25.3) |
Table 2
Instrument | Value | Change from baseline | p-value | |
---|---|---|---|---|
|
||||
Mean±SD | 95% CI | |||
HAQ-DI | ||||
Baseline | 1.29±0.71 | |||
Week 12 | 0.80±0.64 | −0.46±0.60 | −0.60, −0.33 | <0.0001* |
Week 24 | 0.63±0.56 | −0.67±0.67 | −0.83, −0.51 | <0.0001* |
Patients achieving a clinically meaningful improvement in HAQ-DI at week 12† | 52 (65.8) | |||
Patients achieving a clinically meaningful improvement on HAQ-DI at 24 weeks† | 55 (77.5) | |||
EQ-5D-3L | ||||
Baseline | 0.59±0.22 | |||
Week 12 | 0.74±0.18 | 0.15±0.24 | 0.10, 0.20 | <0.0001‡ |
Week 24 | 0.77±0.19 | 0.18±0.25 | 0.12, 0.24 | <0.0001‡ |
SF-36 Physical component summary scores | ||||
Baseline | 34.57±7.76 | |||
Week 12 | 41.26±7.56 | 6.56±6.98 | 7.67, 11.35 | <0.0001‡ |
Week 24 | 43.91±7.07 | 9.51±7.77 | 7.67, 11.35 | <0.0001‡ |
SF-36 Mental component summary scores | ||||
Baseline | 35.88±11.51 | |||
Week 12 | 41.54±11.84 | 5.26±11.62 | 2.66, 7.87 | 0.0001‡ |
Week 24 | 43.00±11.62 | 6.63±12.31 | 3.71, 9.54 | <0.0001‡ |
Values are presented as mean±standard deviation or number (%). HAQ-DI: Health Assessment Questionnaire Disability Index, EQ-5D-3L: EuroQol 5-dimension 3-Level, SF-36: Short Form 36-Item Health Survey, SD: standard deviation, CI: confidence interval. *p-value is from the test of mean change using ANOVA adjusting for baseline disease severity. †Clinically meaningful improvement on HAQ-DI is defined as a −0.22 or greater point improvement. ‡p-value is from the paired t-test testing the mean change.
Table 3
Instrument | Mean±SD | Change from baseline | p-value* | |
---|---|---|---|---|
|
||||
Mean±SD | 95% CI | |||
Percent overall work impairment (%) | ||||
Baseline | 58.27±26.19 | |||
Week 12 | 37.03±26.27 | −19±32 | −32, −5 | 0.0098 |
Week 24 | 32.31±25.86 | −25±31 | −40, −11 | 0.0015 |
Percent activity impairment (%) | ||||
Baseline | 61.71±24.98 | |||
Week 12 | 45.47±27.52 | −15±31 | −22, −8 | <0.0001 |
Week 24 | 38.59±28.35 | −25±34 | −33, −16 | <0.0001 |